HLS – Credit Suisse rates the stock as Neutral
LATEST
- Medicine Branch (N-Z) / Pathology
HLS – Credit Suisse rates the stock as Neutral
Healius has withdrawn FY20 guidance. The company is currently completing around 2500 tests for coronavirus per day but this is not enough to offset the volume drop from fewer GP attendances and the deferral of elective pathology & radiolo.